Achillion: It Can’t Get Any Worse…Or Can It?

Does Achillion Pharmaceuticals (ACHN) have any upside ahead? In a note published today, Leerink analyst Joseph Schwartz upgraded the beaten-down biotech stock to Outperform and lifted his price target to $6 a share, arguing that there is limited downside at current levels even if its foray outside the hepatitis C market continues to hit snags. […]
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>